CD1-HM119F-100μg / 询价
CD1-HM119F-500μg / 询价
CD1-HM119F-500μgx2 / 询价
- 客服电话
- 技术支持
FITC-Compatible Human CD19 Protein
FITC-Compatible Human CD19 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro20-Lys291 [Accession | P15391-1].
The protein has a predicted MW of 60.1 kDa. Due to glycosylation, the protein migrates to 68-72 kDa based on Bis-Tris PAGE result.
Excitation Wavelength: 490 nm
Emission Wavelength: 520 nm
>95% as determined by Bis-Tris PAGE
>95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
FITC-Compatible Human CD19 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of FITC-Compatible Human CD19 is greater than 95% as determined by SEC-HPLC.
FACS Analysis of Anti-CD19 CAR expression. 293T cells were transfected with anti-CD19-scFv and His tag. Cells were incubated with 10 μg/ml FITC-compatible Human CD19, His Tag and PE-labeled protein control. Non-transfected 293T cells and FITC-labeled protein control were used as negative control.
CD19 is a B-lineage-specific transmembrane glycoprotein, the expression of which is maintained on more than 95% B-cell malignancies. This strict lineage restriction makes CD19 an ideal target for immune therapies using chimeric antigen receptors (CARs). T cells engineered to express a chimeric antigen receptor (CAR) against CD19 have recently been FDA approved for the treatment of relapsed or refractory large B-cell lymphoma. Despite the success and curative potential of CD19 CAR T cells, several reports describing disease relapse due to antigen loss are now emerging.
CD19; B4; CVID3; Leu-12; MGC12802
Hirayama AV, Turtle CJ. Toxicities of CD19 CAR-T cell immunotherapy. Am J Hematol. 2019 May;94(S1):S42-S49. doi: 10.1002/ajh.25445. Epub 2019 Mar 6. PMID: 30784102.
